NeuroSense Therapeutics (NRSN) Q4 2025 Earnings
NRSN·Reported April 6, 2026·Before market open
Diluted EPS came in at $-0.22 (-266.7% YoY), missed the $-0.07 consensus by $0.15.
Diluted EPS
$-0.22missed by $0.15
Consensus: $-0.07
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2025 Earnings FAQ
Common questions about NeuroSense Therapeutics's Q4 2025 earnings report.
NeuroSense Therapeutics (NRSN) reported Q4 2025 earnings on April 6, 2026 before market open.
NeuroSense Therapeutics reported diluted EPS of $-0.22 for Q4 2025.
EPS missed the consensus estimate of $-0.07 by $0.15.
Compared to the same quarter a year prior, diluted EPS declined 266.7% from $-0.06.